Skip to main content
. Author manuscript; available in PMC: 2023 Jan 10.
Published in final edited form as: Dev Cell. 2022 Jan 10;57(1):32–46.e8. doi: 10.1016/j.devcel.2021.12.007

Figure 1. CGD transgene GFP labels putative GBM CSC initiated from wild-type neural stem cells.

Figure 1.

(A) Upper panel: Depiction of transgenic products generated from CGD transgene. Cre-ERT2, H2B-eGFP, and hDTR are translated from the same transcript through ribosomal skipping. Lower Panel: Cartoon illustrates localization of GFP proteins in NSC of wild-type SVZ (left) and, upon Cre induction, putative GBM CSC. (B) Hematoxylin and eosin (H&E) staining of spontaneous GBM (dotted red line) in representative brain sagittal section from CGD;Nf1fl/+;Trp53fl/+;Ptenfl/+ mice. Actively dividing GBM cells are highlighted by red circles (right panel). Scale bars in left and right panels: 1mm and 20um. (C) CGD-GBM mice develop high-grade gliomas (HGG). (D) Survival curves demonstrate fully penetrant mortality induced by CGD transgene following tamoxifen administration within three to seven months after induction. (E) Representative FACS sorting images show a 4% GFP+ cell compartment in a spontaneous CGD-GBM. (F) 22 of 26 CGD GBM contain fewer than 6% GFP+ cells. See also Figure S1.